Rudolph Navari to Prospective Studies
This is a "connection" page, showing publications Rudolph Navari has written about Prospective Studies.
Connection Strength
0.296
-
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602). Oncologist. 2023 08 03; 28(8):722-729.
Score: 0.126
-
Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat. 2008 Nov; 112(1):197-201.
Score: 0.043
-
Symptomatic treatment of infections in patients with advanced cancer receiving hospice care. J Pain Symptom Manage. 2005 Aug; 30(2):175-82.
Score: 0.036
-
Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis. Support Care Cancer. 2023 Oct 25; 31(12):654.
Score: 0.032
-
Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Cancer Med. 2023 08; 12(15):15769-15776.
Score: 0.032
-
Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging With a Point-of-Care Perfusion Phantom: A Pilot Study. Invest Radiol. 2019 01; 54(1):16-22.
Score: 0.023
-
Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma. Cancer. 1996 Aug 15; 78(4):789-93.
Score: 0.005